Loading stock data…
$3.95-0.31 (-7.28%)
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally.
Anbio Biotechnology in the Healthcare sector is trading at $3.95 with a market capitalization of $1.3B. The stock is currently near its 52-week low of $3.88, remaining 79.4% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 15 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | — | — | — | — |
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isotherm...